Skip to main content
. Author manuscript; available in PMC: 2010 Aug 31.
Published in final edited form as: Am J Hypertens. 2007 Aug;20(8):866–874. doi: 10.1016/j.amjhyper.2007.02.015

Table 2.

Circulating factors in treated and untreated SHROB rats at termination of study

Group Vehicle (N = 14) Captopril (N = 11) Allylmercaptocaptopril (N = 9)
Glucose (mg/dL) 188 ± 26 141 ± 15 119 ± 5*
Insulin (ng/mL) 4.1 ± 0.9 5.0 ± 0.7 7.5 ± 1.3*
Glucagon (pg/mL) 156 ± 10 147 ± 8 148 ± 12
Triglycerides (mg/dL) 329 ± 24 233 ± 27* 210 ± 20*
Free fatty acids (mmol/L) 0.91 ± 0.05 0.78 ± 0.12 0.64 ± 0.04*

Data are mean ± SEM.

*

Significantly different from vehicle controls, P < .05 according to Newman-Keuls test.

HHS Vulnerability Disclosure